Fig. 2
From: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
![Fig. 2](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12885-018-5110-2/MediaObjects/12885_2018_5110_Fig2_HTML.png)
Kaplan-Meier (KM) plot of PFS showing the interaction between BM and starting dose of afatinib. KM plot showing interaction between presence of BM at start of treatment and starting dose of afatinib in our cohort